Geneva and Montpellier, April 28, 2023 – Neurix SA is delighted to announce that CYTEA BIO SAS has selected our BlastomaBrain™ platform to perform its pre-clinical validation in anticipation of its IND filing with the FDA. CYTEA is developing a novel immunotherapy approach to address an urgent unmet medical need for glioblastoma patients. Glioblastoma models developed by Neurix using patient-derived glioblastoma samples offer the opportunity to test personalised therapies for the disease.
“We are very proud of the fact that our platform has been selected for such an exciting new therapy that offers to transform the lives of patients, and provide an alternative to animal testing for an FDA IND dossier” said Neurix’s CEO Nikolay Zhukovsky.
CYTEA BIO’s CEO, Alan Cookson said: “CYTEA BIO relishes this opportunity to employ the BlastomaBrain™ platform to evaluate the safety and efficacy of our Pin™ immunotherapy treatment for GBM. Pre-clinical platforms that offer more predictive outcomes to animal studies are an important innovation for the pharmaceutical industry”
